Biomarker & Intervention Discovery

Osteoarthritis

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

US DALYs1.71MWHO GHE 2021 · all ages
Global DALYs21.16MWHO GHE 2021 · worldwide
US mortality368 deaths/yrWHO GHE 2021
Global mortality5,018 deaths/yrWHO GHE 2021 · worldwide
NIH funding$147MFY2025 · RCDC estimate
Funding levelUnderfunded
Spontaneous remissionStructural progression is essentially universal over 10+ years without intervention; pain fluctuates but functional…
Best-intervention remissionNo cure or disease modification available; total joint replacement (TJR) achieves 85-90% patient satisfaction and…
Gap sizeLarge for pain management vs disease modification (disease modification doesn't exist); moderate for functional…
Primary barrierbiological + practice
Full remission profile →

Remission & chronicity

Spontaneous remission
Structural progression is essentially universal over 10+ years without intervention; pain fluctuates but functional decline is the expected trajectory; no disease-modifying therapy exists as of 2024
Best-intervention remission
No cure or disease modification available; total joint replacement (TJR) achieves 85-90% patient satisfaction and near-elimination of pain but is not disease reversal; weight loss of >10% reduces pain scores ~50% and slows structural progression; exercise therapy comparable to NSAIDs for pain relief
Gap size
Large for pain management vs disease modification (disease modification doesn't exist); moderate for functional outcomes (exercise and weight loss underutilized vs medication)
Primary barrier
biological + practice
OARSI formally petitioned the FDA in 2016 to recognize OA as a serious disease with no cure and no disease-modifying interventions — confirmed in FDA's criteria. Practice gap: NSAIDs have been first-line for >100 years despite long-term evidence of joint damage acceleration and GI/CV risk; exercise consistently outperforms medication in functional outcomes but is rarely 'prescribed'
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

ACAN 0ADAMTS5 196COL2A1 3CTNNB1 172IL1B 218IL6 173MMP13 198NGF 9PTGS2 299TNF 277

Pipeline results not yet available for this target. Run the pipeline to populate.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ALDUMASTAT inhibits Mechanistic
AGG-523 ? unclear Mechanistic 560.0 nM (IC50)
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic
CHEMBL208009 inhibits Mechanistic 97.0 nM (Ki)
CHEMBL207305 inhibits Mechanistic 1900.0 nM (Ki)
CHEMBL230403 inhibits Mechanistic 20100.0 nM (IC50)
CHEMBL396206 inhibits Mechanistic 1800.0 nM (IC50)
CHEMBL231000 inhibits Mechanistic 1600.0 nM (IC50)
CHEMBL230895 inhibits Mechanistic 1300.0 nM (IC50)
CHEMBL230789 inhibits Mechanistic 11100.0 nM (IC50)
CHEMBL230894 inhibits Mechanistic 1300.0 nM (IC50)
CHEMBL230788 inhibits Mechanistic 1100.0 nM (IC50)
CHEMBL387994 inhibits Mechanistic 900.0 nM (IC50)
CHEMBL230683 inhibits Mechanistic 5300.0 nM (IC50)
CHEMBL397040 inhibits Mechanistic 6700.0 nM (IC50)
CHEMBL397937 inhibits Mechanistic 6800.0 nM (IC50)
CHEMBL230726 inhibits Mechanistic 9200.0 nM (IC50)
CHEMBL230725 inhibits Mechanistic 10000.0 nM (IC50)
CHEMBL396218 inhibits Mechanistic 5300.0 nM (IC50)
CHEMBL230723 inhibits Mechanistic 2500.0 nM (IC50)
CHEMBL396217 inhibits Mechanistic 3200.0 nM (IC50)
CHEMBL230621 inhibits Mechanistic 1700.0 nM (IC50)
CHEMBL230620 inhibits Mechanistic 14800.0 nM (IC50)
CHEMBL395985 inhibits Mechanistic 16200.0 nM (IC50)
CHEMBL230619 inhibits Mechanistic 4900.0 nM (IC50)
CHEMBL230516 inhibits Mechanistic 11600.0 nM (IC50)
CHEMBL395503 inhibits Mechanistic 3500.0 nM (IC50)
CHEMBL230514 inhibits Mechanistic 1400.0 nM (IC50)
CHEMBL230408 inhibits Mechanistic 1800.0 nM (IC50)
CHEMBL232565 inhibits Mechanistic 4200.0 nM (IC50)
CHEMBL391693 inhibits Mechanistic 9000.0 nM (IC50)
CHEMBL442073 inhibits Mechanistic 2100.0 nM (IC50)
CHEMBL231740 inhibits Mechanistic 1100.0 nM (IC50)
CHEMBL232364 inhibits Mechanistic 2500.0 nM (IC50)
CHEMBL393113 inhibits Mechanistic 2200.0 nM (IC50)
CHEMBL392264 inhibits Mechanistic 23200.0 nM (IC50)
CHEMBL233333 inhibits Mechanistic 9100.0 nM (IC50)
CHEMBL391928 inhibits Mechanistic 7100.0 nM (IC50)
CHEMBL233132 inhibits Mechanistic 4200.0 nM (IC50)
CHEMBL393991 inhibits Mechanistic 4600.0 nM (IC50)

Showing top 40 of 196 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM ? unclear Mechanistic
OCRIPLASMIN ? unclear Mechanistic
ALBUTEROL SULFATE ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PP1 inhibits Mechanistic
PF-670462 inhibits Mechanistic
MPI-0479605 ? unclear Mechanistic
SKF-86002 inhibits Mechanistic
SB203580 inhibits Mechanistic
IMATINIB ? unclear Mechanistic
MAPK13-IN-1 inhibits Mechanistic
BAY1217389 ? unclear Mechanistic
NIROGACESTAT ? unclear Mechanistic
NMS-P715 ? unclear Mechanistic
ACUMAPIMOD inhibits Mechanistic
EOSIN_Y ? unclear Mechanistic
DILMAPIMOD inhibits Mechanistic
PRI-724 inhibits Mechanistic
MW150 inhibits Mechanistic
COMPOUND 12 [PMID: 22521646] inhibits Mechanistic
BMS-582949 inhibits Mechanistic
OSUGACESTAT ? unclear Mechanistic
AZD7624 inhibits Mechanistic
VANTICTUMAB ? unclear Mechanistic
ANTI-PD-L1 MONOCLONAL ANTIBODY ? unclear Mechanistic
LOSMAPIMOD inhibits Mechanistic
LENALIDOMIDE ? unclear Mechanistic
NDPPC inhibits Mechanistic
CELECOXIB ? unclear Mechanistic
TRAMETINIB DIMETHYL SULFOXIDE ? unclear Mechanistic
DORAMAPIMOD inhibits Mechanistic
CHEMBL:CHEMBL2172378 ? unclear Mechanistic
RECOMBINANT HUMAN ENDOSTATIN ? unclear Mechanistic
TRICIRIBINE ? unclear Mechanistic
TEMSIROLIMUS ? unclear Mechanistic
AZD6703 inhibits Mechanistic
SAM68 MODULATOR CWP232291 ? unclear Mechanistic
NEFLAMAPIMOD inhibits Mechanistic
LETROZOLE ? unclear Mechanistic
VX-702 inhibits Mechanistic
7-HYDROXYSTAUROSPORINE inhibits Mechanistic
TAK-715 inhibits Mechanistic
FLUORESCEIN SODIUM ? unclear Mechanistic
PEXMETINIB inhibits Mechanistic

Showing top 40 of 172 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ASPIRIN ? unclear Mechanistic
MAFOSFAMIDE ? unclear Mechanistic
DIACETYLRHEIN ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
LANSOPRAZOLE ? unclear Mechanistic
TILUDRONIC ACID ? unclear Mechanistic
GEVOKIZUMAB ~ modulates Mechanistic
LUTIKIZUMAB inhibits Mechanistic
CELASTROL ? unclear Mechanistic
CYTARABINE ? unclear Mechanistic
RILONACEPT inhibits Mechanistic
TT-301 ? unclear Mechanistic
METFORMIN ? unclear Mechanistic
ANTICONVULSANT AGENT ? unclear Mechanistic
ANTIDEPRESSANT AGENT ? unclear Mechanistic
ACITRETIN ? unclear Mechanistic
ERYTHROMYCIN ? unclear Mechanistic
ALTEPLASE ? unclear Mechanistic
OFLOXACIN ? unclear Mechanistic
PENTOXIFYLLINE ? unclear Mechanistic
USTEKINUMAB ? unclear Mechanistic
LITHIUM ? unclear Mechanistic
RALOXIFENE HYDROCHLORIDE ? unclear Mechanistic
MITOGEN-ACTIVATED PROTEIN KINASE INHIBITOR ? unclear Mechanistic
DRUGSATFDA.NDA:008378 ? unclear Mechanistic
NICARDIPINE ? unclear Mechanistic
GLUCOSAMINE ? unclear Mechanistic
BECLOMETHASONE DIPROPIONATE ? unclear Mechanistic
PAREGORIC ? unclear Mechanistic
CEFACLOR ANHYDROUS ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
MELATONIN ? unclear Mechanistic
PENTAMIDINE ? unclear Mechanistic
PRAVASTATIN SODIUM ? unclear Mechanistic
VERAPAMIL ? unclear Mechanistic
THYROGLOBULIN ? unclear Mechanistic
RISEDRONIC ACID ? unclear Mechanistic
AUTOANTIGEN ? unclear Mechanistic
CDP-484 inhibits Mechanistic
ETIDRONIC ACID ? unclear Mechanistic

Showing top 40 of 218 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CISPLATIN ? unclear Mechanistic
ZILTIVEKIMAB ~ modulates Mechanistic
CHINESE HERBS ? unclear Mechanistic
PF-04236921 inhibits Mechanistic
MRA 003 US inhibits Mechanistic
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic
BINETRAKIN ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
SILTUXIMAB inhibits Mechanistic
METRONIDAZOLE ? unclear Mechanistic
CLAZAKIZUMAB inhibits Mechanistic
GALLIUM NITRATE ? unclear Mechanistic
INTERFERON ALFA-2B ? unclear Mechanistic
DULOXETINE HYDROCHLORIDE ? unclear Mechanistic
MEDI-5117 inhibits Mechanistic
GEMFIBROZIL ? unclear Mechanistic
BIAFINE CREAM ? unclear Mechanistic
ETANERCEPT ? unclear Mechanistic
ELSILIMOMAB inhibits Mechanistic
SAQUINAVIR ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
LINEZOLID ? unclear Mechanistic
IFOSFAMIDE ? unclear Mechanistic
OLOKIZUMAB inhibits Mechanistic
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
SELENIUM ? unclear Mechanistic
SIRUKUMAB inhibits Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
ECHINACEA PREPARATION ? unclear Mechanistic
ENZYME INHIBITOR ? unclear Mechanistic
FENOFIBRATE MICRONIZED ? unclear Mechanistic
VITAMIN K ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
RIBAVIRIN ? unclear Mechanistic
VITAMIN A PALMITATE ? unclear Mechanistic
ARSENIC TRIOXIDE ? unclear Mechanistic
DIHYDROSPHINGOSINE ? unclear Mechanistic
LEVOFLOXACIN ANHYDROUS ? unclear Mechanistic

Showing top 40 of 173 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CURCUMIN ? unclear Mechanistic
REBIMASTAT inhibits Mechanistic
DOXYCYCLINE CALCIUM inhibits Mechanistic
APRATASTAT inhibits Mechanistic
PRINOMASTAT ? unclear Mechanistic 1.5 nM (IC50)
DOXYCYCLINE ANHYDROUS inhibits Mechanistic
CTS-1027 inhibits Mechanistic 2.0 nM (IC50)
ILOMASTAT ? unclear Mechanistic
DOXYCYCLINE HYCLATE ? unclear Mechanistic
DOXYCYCLINE ? unclear Mechanistic
CHEMBL348210 inhibits Mechanistic 3.0 nM (IC50)
CHEMBL80814 inhibits Mechanistic 2.0 nM (IC50)
CHEMBL346624 inhibits Mechanistic 0.7 nM (IC50)
CHEMBL276119 inhibits Mechanistic 2.0 nM (IC50)
CHEMBL78934 inhibits Mechanistic 5.0 nM (IC50)
CHEMBL78369 inhibits Mechanistic 1.0 nM (IC50)
CGS-27023A inhibits Mechanistic 8.0 nM (IC50)
CHEMBL151591 inhibits Mechanistic 3.0 nM (IC50)
CHEMBL80453 inhibits Mechanistic 4.0 nM (IC50)
CHEMBL312432 inhibits Mechanistic 6.0 nM (IC50)
CHEMBL150655 inhibits Mechanistic 0.2 nM (IC50)
CHEMBL306617 inhibits Mechanistic 2.0 nM (IC50)
CHEMBL79111 inhibits Mechanistic 2.0 nM (IC50)
CHEMBL78798 inhibits Mechanistic 1.0 nM (IC50)
CHEMBL440355 inhibits Mechanistic 0.5 nM (IC50)
CHEMBL80969 inhibits Mechanistic 2.0 nM (IC50)
CHEMBL78909 inhibits Mechanistic 1.0 nM (IC50)
CHEMBL76137 inhibits Mechanistic 3.0 nM (IC50)
CHEMBL310340 inhibits Mechanistic 1.4 nM (IC50)
CHEMBL150027 inhibits Mechanistic 0.4 nM (IC50)
CHEMBL346442 inhibits Mechanistic 0.2 nM (IC50)
CHEMBL76836 inhibits Mechanistic 3.0 nM (IC50)
CHEMBL150077 inhibits Mechanistic 0.3 nM (IC50)
CHEMBL357796 inhibits Mechanistic 8.0 nM (IC50)
CHEMBL312429 inhibits Mechanistic 2.0 nM (IC50)
CHEMBL78549 inhibits Mechanistic 1.0 nM (IC50)
CHEMBL78508 inhibits Mechanistic 2.0 nM (IC50)
CHEMBL80732 inhibits Mechanistic 2.0 nM (IC50)
CHEMBL309311 inhibits Mechanistic 1.0 nM (IC50)
CHEMBL151399 inhibits Mechanistic 4.0 nM (IC50)

Showing top 40 of 198 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
MEDI-578 inhibits Mechanistic
CERE-110 ? unclear Mechanistic
FASINUMAB inhibits Mechanistic
TANEZUMAB inhibits Mechanistic
FRUNEVETMAB ~ modulates Mechanistic
FULRANUMAB inhibits Mechanistic
BEDINVETMAB ~ modulates Mechanistic
PG-110 inhibits Mechanistic
CHEMBL1397270 inhibits Mechanistic 1000.0 nM (IC50)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CARPROFEN inhibits Mechanistic 102.0 nM (IC50)
INDOMETHACIN SODIUM inhibits Mechanistic
DARBUFELONE ? unclear Mechanistic
MEFENAMIC ACID inhibits Mechanistic
MECLOFENAMATE SODIUM inhibits Mechanistic
DICLOFENAC SODIUM inhibits Mechanistic
CAPECITABINE ? unclear Mechanistic
PIRPROFEN inhibits Mechanistic
ESFLURBIPROFEN inhibits Mechanistic
SULFASALAZINE inhibits Mechanistic
BROMFENAC ? unclear Mechanistic
IBUPROFEN, SODIUM SALT inhibits Mechanistic
ALOXIPRIN inhibits Mechanistic
TENOXICAM ? unclear Mechanistic
FLURBIPROFEN inhibits Mechanistic
SALICYLIC ACID ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
DEXKETOPROFEN inhibits Mechanistic
ETORICOXIB inhibits Mechanistic
LUMIRACOXIB inhibits Mechanistic
SUPROFEN inhibits Mechanistic
NS-398 ? unclear Mechanistic
NABUMETONE inhibits Mechanistic
URSOLIC ACID ? unclear Mechanistic
IBUPROFEN LYSINE inhibits Mechanistic
ACECLOFENAC inhibits Mechanistic
IBUFENAC inhibits Mechanistic
BALSALAZIDE ? unclear Mechanistic
DIFLUNISAL inhibits Mechanistic
BALSALAZIDE DISODIUM inhibits Mechanistic
VACCINE ? unclear Mechanistic
KETOROLAC TROMETHAMINE inhibits Mechanistic
BENZYDAMINE HYDROCHLORIDE inhibits Mechanistic
TIAPROFENIC ACID ? unclear Mechanistic
RALOXIFENE HYDROCHLORIDE ? unclear Mechanistic
NAPROXCINOD inhibits Mechanistic
IGURATIMOD inhibits Mechanistic
ETODOLAC inhibits Mechanistic
DICLOFENAC ETALHYALURONATE SODIUM inhibits Mechanistic
ROFECOXIB inhibits Mechanistic 530.0 nM (IC50)

Showing top 40 of 299 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
NERELIMOMAB inhibits Mechanistic
CROMOLYN SODIUM ? unclear Mechanistic
PLACULUMAB inhibits Mechanistic
METHYLENE BLUE ? unclear Mechanistic
ALTEPLASE ? unclear Mechanistic
CARBOPLATIN ? unclear Mechanistic
GENTAMICIN ? unclear Mechanistic
GOLIMUMAB inhibits Mechanistic
BUPIVACAINE ? unclear Mechanistic
PENTOXIFYLLINE ? unclear Mechanistic 85000.0 nM (IC50)
BENZO[E]PYRENE ? unclear Mechanistic
THALIDOMIDE ? unclear Mechanistic
PYRAZINAMIDE ? unclear Mechanistic
GLIMEPIRIDE ? unclear Mechanistic
OMEPRAZOLE ? unclear Mechanistic
LENERCEPT inhibits Mechanistic
ADALIMUMAB inhibits Mechanistic
PRAZOSIN HYDROCHLORIDE ? unclear Mechanistic
REMTOLUMAB ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
LENABASUM ? unclear Mechanistic
MAGNESIUM SULFATE ANHYDROUS ? unclear Mechanistic
PICIBANIL ? unclear Mechanistic
FLUOCINOLONE ACETONIDE ? unclear Mechanistic
MILTEFOSINE ? unclear Mechanistic
HOMIDIUM BROMIDE ? unclear Mechanistic
OZORALIZUMAB inhibits Mechanistic
PEGSUNERCEPT inhibits Mechanistic
CERTOLIZUMAB PEGOL inhibits Mechanistic
THERAPEUTIC HORMONE ? unclear Mechanistic
NAFAMOSTAT ? unclear Mechanistic
FOLIC ACID ? unclear Mechanistic
ABBV-257 ? unclear Mechanistic
RISPERIDONE ? unclear Mechanistic
COVA322 ? unclear Mechanistic
HYDROXYCHLOROQUINE ? unclear Mechanistic
CERTOLIZUMAB ? unclear Mechanistic
AN0128 ? unclear Mechanistic
5,7-DIHYDROXY-4-METHYLCOUMARIN ? unclear Mechanistic
SORAFENIB ? unclear Mechanistic

Showing top 40 of 277 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-06.

No recent clinical trials found on ClinicalTrials.gov for this condition.


Agents Found By Disease-Level Search

Searched directly from “Osteoarthritis” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

60 agents shown (approved or with trial evidence) — 59 not found by the gene-target search above.

transient immune-modulationNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT05835895 NCT05835895

FX006 32 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02762370

TCA IR 40 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02762370

Kaia hip and knee pain applicationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04615377

DELTA Revision acetabular cupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06359301

Ketoprofen Topical Patch , 20%NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00365586

MPact CupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03897595

YYD302 2mlNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02965495

YYD302 3mlNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02965495

Placebo 3mlNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02965495

GNSC-001NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05835895

Fit & Strong!NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04536727

Wait listNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04536727

tai chiNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03660254

Corticosteroid injection (CSI)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07217405

Low-dose radiotherapy (LDRT)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07217405

stem cell injectionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01499056

Autologous cell therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03984461

Operative (partial arthroscopy)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00549172

Conservative (diagnostic arthroscopy)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00549172

chondroitin sulfateNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02079727

celecoxib

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02079727

Non-image-based Computer-Assisted Navigation with Bone MorphingNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07574775

P.F.C. Sigma KneeNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00734019

Sodium Hyaluronate (Hyalgan)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01267214

Osteotomy aloneNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01267214

Medacta GMK Sphere® Medial Knee ProsthesisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02501733

TriathlonNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05842538

Total knee replacement with the ROCC® knee prosthesisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02127619

AS Domelock SystemNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03312465

Vitamin DNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01176344

Total Hip ArthroplastyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06640764

OraVescent FentanylNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00343733

Lifestyles ANOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01142349

Lifestyles BNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01142349

Lifestyles CNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01142349

Aquamid reconstructionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03060421

Stem Cell Support FormulaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04661267

Application ARTHeNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04750304

Zimmer Patient specific instrumentsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02096393

Standard instrumentationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02096393

Pregabalin or Duloxetine or PlaceboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02612233

barbed sutureNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03031314

standard sutureNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03031314

Tapentadol (CG5503) Extended Release (ER)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00487435

Synvisc-One (hylan G-F 20)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01618708

Vivacit-E LinerNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03226808

Liposomal bupivacaineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02762071

Interscalene Nerve BlockNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02762071

BioPolyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06915363

surgical standard of care (SSOC)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06915363

Flywheel exerciseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04588558

Electrotherapy groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04588558

Evicel fibrin sealantNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01235715

Traumeel® / Zeel® Injectable SolutionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01887678

injection of Filtered Autologous Adipose TissueNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04567732

SM04690NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02536833

ESWTNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04243135

Nudge interventionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07330492

CATALYSTEMNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06564636

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
VitalScan4PACVS Remote physiological monitoring study for post-acute COVID-19 vaccination syndrome.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.